ReviewDrugs2020
HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals.
Review in Drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial.Clinical and translational science · 2024Trial
- The Role of Healthcare-Related Experiences in Willingness and Preference for Long-Acting Injectable PrEP (LAI-PrEP) Among Transfeminine People in the United States.AIDS and behavior · 2026Article
- Longitudinal Analysis of Substance Use as a Predictor PrEP Use and Adherence Among Young Transgender Women and Nonbinary Individuals.AIDS and behavior · 2026Article
- Barriers to Same-Day Pre-exposure Prophylaxis (PrEP) Implementation in Federally Funded HIV Clinics Within High-Burden Areas of the U.S.: A Coincidence Analysis.AIDS and behavior · 2026Article
- Community-Partnered Development of Behavioral Economic Incentives in a Pre-exposure Prophylaxis Intervention for Transgender and Nonbinary Clients in Los Angeles.Research square · 2025Article
- Gender-Affirming Care as a Predictor of HIV Pre-Exposure Prophylaxis Use and Adherence Among Young Trans Feminine Adults: A Coincidence Analysis.Prevention science : the official journal of the Society for Prevention Research · 2025Article
- Preference for Long-Acting HIV Prevention Methods Among Transgender Women Vulnerable to HIV in Eastern and Southern United States: Findings from the LITE Study.AIDS and behavior · 2025Article
- Review protocol for a systematic review and meta-analysis on HIV inequities in transgender and non-binary populations.BMJ open · 2025Article
- Access of transgender people and transvestites to pre-exposure prophylaxis for HIV in Brazil: a descriptive study, 2018-2023.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025Article
- Influence of Stigma on Engagement in HIV Care and Adherence to Antiretroviral Therapy in Specialized HIV Clinics Targeting Men Who Have Sex with Men and Transgender Women in Lima, Peru.AIDS and behavior · 2024Article
- Article
- Gender Identity Disclosure and Healthcare Services Uptake Among Chinese Transgender Individuals in China: Results from a Cross-Sectional Study.International journal of sexual health : official journal of the World Association for Sexual Health · 2024Article
- Understanding Barriers and Facilitators of Pre-exposure Prophylaxis (PrEP) Among Transgender and Gender Diverse Adults in an Integrated Health Care System.AIDS and behavior · 2023Article
- Determinants of Pre-exposure Prophylaxis (PrEP) Implementation in Transgender Populations: A Qualitative Scoping Review.AIDS and behavior · 2023Article
- Inclusion of Transgender and Gender Diverse People in Phase III Trials: Examples from HIV Pharmacologic Prevention Studies.Clinical pharmacology and therapeutics · 2023Review
- Breaking the Binary: How Clinicians Can Ensure Everyone Receives High Quality Reproductive Health Services.Open access journal of contraception · 2023Review
- Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis.The Journal of antimicrobial chemotherapy · 2022Article
- HIV and STI positivity rates among transgender people attending two large STI clinics in the Netherlands.Sexually transmitted infections · 2022Article
- Does Gender Affirming Hormone Therapy Increase the Risk of Kidney Disease?Seminars in nephrology · 2022Review
- Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts.Open forum infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
HIV prevalence is elevated among transgender populations with an estimated 13.7% of transgender adults living with HIV in the USA. In addition, transgender people experience significant disparities in biomedical HIV prevention and treatment. The efficacy of topical microbicides for prevention of HIV acquisition have not been tested among transgender people and may be impacted by hormonal therapies and/or surgeries undertaken by some transgender people to align their anatomy with their gender identity. Low pre-exposure prophylaxis (PrEP) uptake and adherence as well as potential drug-hormone interactions impact the efficacy of PrEP among transgender women. Few transgender men have been engaged in the PrEP continuum, and they have been largely excluded from PrEP research until very recently. Prioritisation of hormone therapy over HIV treatment as well as concerns about drug-hormone interactions may impact transgender women's adherence to antiretroviral therapy. More research is needed to clarify the clinical significance of identified drug-hormone interactions and better inform interventions to improve HIV prevention and care for transgender people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.